Please note – you will leave a website owned by MacroGenics, Inc.
MacroGenics is not responsible for any content on the third party website.
MacroGenics has a diverse portfolio of oncology product candidates with several clinical trials currently underway or planned for the near future. Set forth below is the company’s development pipeline of product candidates for which we have retained commercialization or other important rights in the U.S. or more broadly (as of July 2022).
In addition to the molecules identified below, MacroGenics has out-licensed various other clinical-stage product candidates for which it retains certain economic rights. These include retifanlimab and teplizumab.
Program (Target) | Potential Indication(s) | First-in-Human (Phase 1) | Proof-of-Concept (Phase 2) |
Pivotal (Phase 3) |
Major Market Rights | ||
---|---|---|---|---|---|---|---|
MGC018 (B7-H3) |
mCRPC, NSCLC, SCCHN, Melanoma |
placeholder
|
![]() |
||||
Multiple Solid Tumors (+lorigerlimab) |
placeholder
|
||||||
Lorigerlimab (PD-1 × CTLA-4) |
MSS CRC, NSCLC, mCRPC, Melanoma |
placeholder
|
![]() |
||||
Tebotelimab (PD-1 × LAG-3) |
Solid Tumors & Heme Malignancies |
placeholder
|
![]() |
Greater China![]() |
|||
IMGC936 (ADAM9) |
Multiple Solid Tumors |
placeholder
|
50/50 ![]() ![]() |
||||
MGD024 (CD123 × CD3) |
CD123+ Heme Malignancies |
placeholder
Plan to initiate in mid-2022a
|
![]() |
Phase 1 | Phase 2 | Phase3 |
---|---|---|
placeholder
|
Phase 1 | Phase 2 | Phase3 |
---|---|---|
placeholder
|
Major Market Rights:
Phase 1 | Phase 2 | Phase3 |
---|---|---|
placeholder
|
Major Market Rights:
Phase 1 | Phase 2 | Phase3 |
---|---|---|
placeholder
|
Major Market Rights:
Phase 1 | Phase 2 | Phase3 |
---|---|---|
placeholder
|
Major Market Rights:
Phase 1 | Phase 2 | Phase3 |
---|---|---|
placeholder
Plan to initiate in mid-2022a |
Major Market Rights: